Drilldown: Medicines
Use the filters below to narrow your results.
generic:
brand:
Efudex (topical), Carac (topical), Fluoroplex (topical); generic IV (1) ·
Mag-Ox, Slow-Mag, MagCitrate, Milk of Magnesia (hydroxide); IV sulfate generic (1) ·
Many generics/OTC (1) ·
Mucinex, Robitussin, Tussin (1) ·
Retin-A, Renova, Atralin, Avita, Tretin-X, Refissa, Altreno; Vesanoid (oral, APL) (1) ·
Stromectol (oral, generic), Sklice (lice, topical), Soolantra (rosacea, topical 1%) (1) ·
Tums, Caltrate, Os-Cal, Citracal; many generics (1)
classes:
APL)]] (1) ·
hydroxide)]] (1) ·
torsades)]] (1) ·
[[:Category:Antacids|Antacid (carbonate)]] (1) ·
[[:Category:Antacids|Antacid (hydroxide)]] (1) ·
[[:Category:Antiarrhythmics|Antiarrhythmic (IV sulfate (1) ·
[[:Category:Antimetabolites|Antimetabolite (pyrimidine analog)]] (1) ·
[[:Category:Antineoplastics|Antineoplastic (oral (1) ·
[[:Category:Antineoplastics|Antineoplastic]] (1) ·
[[:Category:Antiparasitics|Antiparasitic]] (1) ·
[[:Category:B-vitamins|B-vitamin]] (1) ·
[[:Category:Calcium_supplements|Calcium supplement]] (1) ·
[[:Category:Electrolyte_replacements|Electrolyte replacement]] (2) ·
[[:Category:Expectorants|Expectorant]] (1) ·
[[:Category:Macrocyclic_lactones|Macrocyclic lactone (avermectin)]] (1) ·
[[:Category:Mucolytics|Mucolytic]] (1) ·
[[:Category:Osmotic_laxatives|Osmotic laxative (citrate (1) ·
[[:Category:Retinoids|Retinoid]] (1) ·
[[:Category:Topical_retinoids|Topical retinoid]] (1) ·
[[:Category:Vitamins|Vitamin]] (1)
mechanism:
None (4) ·
'"`UNIQ--vote-0000104D-QINU`"' Adequate hydration is at least as important as the drug in producing the expectorant effect clinically. Used in combination with dextromethorphan, decongestants, or antihistamines in many proprietary OTC cold preparations. (1) ·
'"`UNIQ--vote-0000124C-QINU`"' The 400 mg/d dose for migraine prophylaxis is supported by randomized trials (Schoenen 1998) and remains a low-risk evidence-based supplement option. Characteristic bright-yellow urine fluorescence with high-dose oral supplementation. (1) ·
'"`UNIQ--vote-00001302-QINU`"' Renally cleared; accumulation in advanced CKD can produce neuromuscular and cardiac depression. Hypomagnesemia frequently co-exists with hypokalemia and is often the reason refractory potassium loss does not correct until magnesium is repleted. (1)
uses:
'"`UNIQ--vote-00000BA0-QINU`"', '"`UNIQ--vote-00000BA1-QINU`"', '"`UNIQ--vote-00000BA2-QINU`"' (1) ·
'"`UNIQ--vote-0000104E-QINU`"', '"`UNIQ--vote-0000104F-QINU`"' (1) ·
'"`UNIQ--vote-0000108C-QINU`"', '"`UNIQ--vote-0000108D-QINU`"', '"`UNIQ--vote-0000108E-QINU`"', '"`UNIQ--vote-0000108F-QINU`"', '"`UNIQ--vote-00001090-QINU`"', '"`UNIQ--vote-00001091-QINU`"' (1) ·
'"`UNIQ--vote-000011BA-QINU`"', '"`UNIQ--vote-000011BB-QINU`"', '"`UNIQ--vote-000011BC-QINU`"', '"`UNIQ--vote-000011BD-QINU`"' (1) ·
'"`UNIQ--vote-0000124D-QINU`"', '"`UNIQ--vote-0000124E-QINU`"', '"`UNIQ--vote-0000124F-QINU`"' (1) ·
'"`UNIQ--vote-000012B7-QINU`"', '"`UNIQ--vote-000012B8-QINU`"', '"`UNIQ--vote-000012B9-QINU`"', '"`UNIQ--vote-000012BA-QINU`"', '"`UNIQ--vote-000012BB-QINU`"' (1) ·
'"`UNIQ--vote-00001303-QINU`"', '"`UNIQ--vote-00001304-QINU`"', '"`UNIQ--vote-00001305-QINU`"', '"`UNIQ--vote-00001306-QINU`"', '"`UNIQ--vote-00001307-QINU`"', '"`UNIQ--vote-00001308-QINU`"', '"`UNIQ--vote-00001309-QINU`"' (1)
starting dose:
200-400 mg PO q4h (IR); 600-1200 mg PO q12h (Mucinex 12-Hour ER) (1) ·
Migraine prophylaxis: 400 mg PO daily; deficiency replacement 5-30 mg/d (1) ·
Oral: 1000-1500 mg elemental calcium/day in divided doses for supplementation; IV gluconate 1 g (4.65 mEq) over 5-10 min for hyperkalemia or symptomatic hypocalcemia (1) ·
Replacement oxide 400-800 mg/d in divided doses (high diarrhea rate); citrate 200-400 mg/d (better tolerated, better absorbed); IV sulfate 1-2 g over 5-60 minutes for hypomagnesemia or torsades; eclampsia 4-6 g IV loading then 1-2 g/h (1) ·
Strongyloides 200 mcg/kg PO single dose; scabies 200 mcg/kg PO repeated at 7-14 days; onchocerciasis 150 mcg/kg q6-12 months (1) ·
Topical: 0.5-5% cream/solution to lesions BID × 2-4 weeks; systemic IV: regimen-specific in cancer chemotherapy (1) ·
Topical: pea-sized amount to dry face at bedtime, building from 2-3×/week to nightly as tolerated; oral APL: 45 mg/m²/d in divided doses (1)
preparations:
0.5% (Carac), 1% (Fluoroplex), 5% (Efudex) topical creams/solutions; 50 mg/mL IV (1) ·
100, 200, 400 mg IR tablets; 600 mg, 1200 mg Mucinex ER tablets; many liquid formulations and combination products with dextromethorphan, pseudoephedrine, antihistamines (1) ·
25, 50, 100, 250, 400 mg tablets; OTC (1) ·
3 mg tablets (Stromectol); 0.5% topical lotion (Sklice); 1% topical cream (Soolantra) (1) ·
Carbonate 200, 400, 500, 600 mg elemental tablets and chewables; citrate 200, 250, 315 mg elemental; gluconate 1 g (94 mg elemental, 4.65 mEq) IV; chloride 1 g (270 mg elemental, 13.6 mEq) IV (1) ·
Oxide 400, 500 mg tablets (240, 300 mg elemental); citrate 100, 150, 200 mg tablets; hydroxide oral suspension 400 mg/5 mL; sulfate IV 500 mg/mL ampules (1) ·
Topical 0.01-0.1% creams, gels, micropsheres, lotions; oral 10 mg capsules (Vesanoid) (1)
fda max:
2.4 g/d (1) ·
Indication-specific; renal clearance limits tolerable cumulative dosing (1) ·
No strict ceiling for water-soluble vitamin; UL not set (1) ·
Single 200-400 mcg/kg per dose for systemic indications (1) ·
Topical: nightly; oral APL: 45 mg/m²/d (1) ·
Topical: nightly; systemic: regimen-specific (1) ·
~2500 mg elemental/d combined diet + supplements (chronic; UL) (1)
routes:
onset:
30 minutes (1) ·
Acute: minutes (IV); chronic: bone effect over months (1) ·
Hours to days (1) ·
Migraine effect after 1-3 months of daily use (1) ·
Oral: hours; IV: minutes (1) ·
Topical: inflammation, erythema, crusting at 2 weeks; complete response weeks to months after course (1) ·
Topical: irritation within days; acne improvement 6-12 weeks; oral APL response within days (1)
duration: (Click arrow to add another value)
halflife:
Not meaningfully described (electrolyte) (1) ·
Not meaningfully described (electrolyte; renally cleared) (1) ·
~0.5-2 hours (oral)'"`UNIQ--ref-00000BA3-QINU`"' (1) ·
~1 hour'"`UNIQ--ref-00001050-QINU`"' (1) ·
~1-2 hours plasma (riboflavin itself); FAD/FMN tissue cofactors are continuous (1) ·
~10-20 minutes systemically (rapid hepatic and erythrocyte dihydropyrimidine dehydrogenase clearance)'"`UNIQ--ref-000011BE-QINU`"' (1) ·
~16-18 hours'"`UNIQ--ref-00001092-QINU`"' (1)
bioavailability:
Carbonate ~30-40% (best with food and acid); citrate ~24% (absorbable without acid; preferred in achlorhydria, PPI use, post-bariatric) (1) ·
High (oral)'"`UNIQ--ref-00001051-QINU`"' (1) ·
Highly salt-dependent: citrate ~25-30%; oxide ~4% (limited and causes osmotic diarrhea); chloride ~12% (1) ·
Topical: minimal systemic absorption (oral systemic 5-FU not used due to poor and variable absorption)'"`UNIQ--ref-000011BF-QINU`"' (1) ·
Topical: minimal systemic absorption with normal skin; oral: variable, induced metabolism with repeated dosing'"`UNIQ--ref-00000BA4-QINU`"' (1) ·
~50-60% (oral; food enhances) (1) ·
~60% (oral; substantially increased with high-fat meal)'"`UNIQ--ref-00001093-QINU`"' (1)
pregnancy:
None (1) ·
Generally considered acceptable.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
IV sulfate is the cornerstone of eclampsia/preeclampsia management; oral replacement also safe.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; risk-benefit case by case; pregnancy is not a strict contraindication in WHO mass drug administration programs.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Routinely supplemented in pregnancy; needs higher in pregnancy and lactation.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Safe at replacement and supplement doses.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Topical: avoid; systemic: contraindicated in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
legal:
OTC (oral salts) and [[USLegal:Prescription only|Rx-only]] (IV) in US (1) ·
OTC (oral supplements) and [[USLegal:Prescription only|Rx-only]] (IV) in US (1) ·
OTC in US (2) ·
[[USLegal:Prescription only|Rx-only]] in US (2) ·
[[USLegal:Prescription only|Rx-only]] in US (the veterinary preparations are not for human use) (1)
Showing below up to 7 results in range #1 to #7.